Learn more about treatment with PIQRAY.
For US residents only.
PIK3CA mutations have been linked to cancer growth. But together, PIQRAY and fulvestrant is a treatment that can help slow the progression of HR+, HER2- metastatic breast cancer (mBC) with a PIK3CA mutation.
PIQRAY was studied in a clinical trial that included 572 postmenopausal women and men, with HR+, HER2- metastatic breast cancer (mBC) who had progressed on or after an aromatase inhibitor (a hormone therapy). Of the 341 people who tested positive for the PIK3CA mutation, 169 took PIQRAY + fulvestrant (hormone therapy), while 172 took fulvestrant alone.
People who tested positive for a PIK3CA mutation and took PIQRAY + fulvestrant lived progression-free for almost twice as long as those who took fulvestrant alone.
Additional results of the trial showed that PIQRAY and fulvestrant worked together to shrink tumors in people with a PIK3CA mutation who had tumors large enough to measure. Of the 262 people with measurable disease, 126 took PIQRAY + fulvestrant and 136 took fulvestrant alone.